BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Genesis Biopharma Announces 1-for-100 Reverse Stock Split and Corporate Name Change to "Lion Biotechnologies, Inc."


9/26/2013 10:15:27 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LOS ANGELES--(BUSINESS WIRE)--Genesis Biopharma, Inc. (OTCBB: GNBP), today announced that a 1-for-100 reverse stock split will be effective, and reflected in the price of its common stock, when trading opens on September 26, 2013. The Company is simultaneously changing its name to Lion Biotechnologies, Inc. The reverse stock split applies to all of the outstanding shares of Genesis Biopharma’s common stock, reducing the number of current outstanding shares from 1,509,381,194 to approximately 15,094,000 shares. The Company’s common stock will trade under the symbol “GNBPD” for a period of 20 trading days as a result of the reverse stock split, and common shares will also trade under a new CUSIP number. “The name change to Lion Biotechnologies reflects the Company’s transition to a new management team and board of directors, along with the adoption of a broader growth strategy,” said Manish Singh, Ph.D., President and Chief Executive Officer of Genesis Biopharma/Lion Biotechnologies. “In addition to optimizing the potential of our current T-cell technology for treating Stage IV metastatic melanoma, we plan to develop promising next-generation tumor-infiltrating lymphocytes (TILs), and engineer an automated manufacturing process that could significantly reduce the cost of producing T-cells.”

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES